<DOC>
	<DOCNO>NCT02606266</DOCNO>
	<brief_summary>Congenital cytomegalovirus ( CMV ) infection lead cause non-genetic neurosensory deafness affect 0.5 1 % birth . Twenty thirty per cent child develop deafness , progress gradually profound bilateral deafness . No curative treatment currently offer deterioration hear management involve use hear aid cochlear implant . Many study describe utility antiviral treatment course deafness . These mostly involve neonate multi-system symptomatic form infection give 6 week ganciclovir possibly switch valganciclovir , show benefit stabilise auditory loss , even improvement .</brief_summary>
	<brief_title>Evaluation Benefit Antiviral Treatment With Valganciclovir Congenital CMV Infection-related Deafness Hearing Balance</brief_title>
	<detailed_description>Congenital cytomegalovirus ( CMV ) infection lead cause non-genetic neurosensory deafness affect 0.5 1 % birth . Twenty thirty per cent child develop deafness , progress gradually profound bilateral deafness . No curative treatment currently offer deterioration hear management involve use hear aid cochlear implant . Many study describe utility antiviral treatment course deafness . These mostly involve neonate multi-system symptomatic form infection give 6 week ganciclovir possibly switch valganciclovir , show benefit stabilise auditory loss , even improvement .</detailed_description>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Children â‰¥ 6 month old &lt; 12 year old Past history proven congenital CMV infection Auditory threshold 40 90 dB least 1 ear . Bilateral deafness &gt; 90 dB Contraindication valganciclovir , particularly : Neutropenia know neutrophil count &lt; 500/mm3 , Hb &lt; 8g/dl platelet &lt; 25,000/mm3 ( FBC confirm randomisation ) Past history neutropenia valganciclovir allergy compound Renal impairment creatinine clearance &lt; 10 ml/min/1.72m2 ( confirmation renal function randomisation ) accord Schwartz equation Patients antiviral treatment Gastrointestinal absorption problem Patients participate biomedical research project medicinal product similar product</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>